DALLAS, Jan. 29, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Repros Therapeutics Inc. (Nasdaq:RPRX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/RPRX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.
Message Board Search for RPRX: http://www.boardcentral.com/boards/RPRX
In the report, the analyst notes:
“Net loss for the three-month period ended September 30, 2009, was ($10.2) million or ($0.66) per share as compared to a net loss of ($6.6) million or ($0.51) per share for the same period in 2008. The net loss for the nine-month period ended September 30, 2009, was ($25.9) million or ($1.69) per share as compared to a net loss of ($19.3) million or ($1.51) per share for the same period in 2008. The increase in loss for both the three and nine-month periods ended September 30, 2009, as compared to the same period in 2008 was primarily due to an increase in RPRX’s clinical development activities for Proellex® …
“RPRX recently announced that the Company and its consultants participated in a teleconference with the Division of Reproductive and Urologic Products of the FDA on January 25, 2010. The primary purpose of the meeting was to gain a better understanding of the FDA’s position regarding the use of Repros’ oral Androxal® product in the treatment of men with secondary hypogonadism wishing to preserve their fertility. The Company’s data supports the notion that the negative feedback of exogenous testosterone administered by any route suppresses the hypothalamic–pituitary axis and hence spermatogenesis.”
To read the entire report visit: http://www.investorsoup.com/lp/RPRX
See what investors say about RPRX at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.